Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced ...
Moderna and Merck’s mRNA cancer vaccine, combined with Keytruda, showed promise in preventing melanoma recurrence, according ...
Merck and Moderna's mRNA cancer vaccine hit its Phase 3 trial endpoint, showing improved recurrence-free survival in melanoma ...
Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of melanoma recurrence and spread in a ...
A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...
Moderna's melanoma mRNA vaccine had a major Phase 3 breakthrough. Here's what's next and when it could become available for skin cancer patients.
Moderna's mRNA vaccine combined with Merck's immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the ...
A new vaccine is changing how doctors treat certain skin cancer patients, according to doctors in the ArkLaTex.
Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug ...
New phase 3 results for Moderna and Merck’s personalized mRNA melanoma vaccine support earlier findings showing a 49% lower ...
Moderna’s mRNA vaccine combined with Merck’s immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the companies said on Wednesday, ...
Merck and Moderna say their personalized cancer vaccine reduced melanoma recurrence and spread in a Phase 3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results